SBIR/STTR Research Award

Dissolvable Materials for Photochemical Tissue Bonding

Award identifier a2a1d628eb2c69b0e361df3e5b3a83580f93108994fbba900fd5ef67a187c87dAwarding agency Department of Defense · Defense Health Agency

Award amount

$1,099,946

Program and phase

STTR · Phase II

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Defense Health Agency
Recipient company
Saxon Glass Technologies, Inc.
Proposal award date
2023-03-17
Contract end date
2025-07-16
UEI
UN9RJZGMEQA3
Solicitation number
21.C
Topic code
DHA21C-001

Research abstract

This PHASE II two-year proposal is designed to expand upon the knowledge gained already in the PHASE I research regarding the development of rapid bioresorbable glasses to bring us to the making of prototype stents which would be ready for testing in animals and humans. Motivated by the success of PHASE I research, wherein several bioresorbable glasses in the Na2O-K2O-CaO-B2O3-P2O5 have been developed, our two-year PHASE II research program aims to optimize two or three specific compositions for dissolution behavior in simulated biofluid, hygroscopicity, mechanical ruggedness, and biocompatibility. The last topic will be studied by our research partner Penn State University. Phase separation behavior of the glass with heat-treatment, subsequent partial crystallization to develop glass-ceramic objects will be studied using XRD, TEM, and ionic leaching kinetics to follow preferential dissolution, if any. Additional modified chemical strengthening may be applied to improve the mechanical strength which would allow thinner but more rugged stent structures to be made with less material to be dissolved. Stents will be made either by a direct drawn tubing or by 3D additive manufacturing process. The latter process enables us to make complex shapes. Our Research Partner Co-PI, Professor James Adair, is a well-recognized bioglass researcher; being a protégé of the late Professor Larry Hench (often called the Father of bioglass). In that respect, Dr. Adair is one of the best to conduct transition research from our Phase I bioglasses to Phase II and moving over to Phase III with little to no learning curve in between. Penn State offers relevant biomedical engineering research experience and has world-class facilities. The biocompatibility testing procedures conducted by Penn State will be consistent with ISO 10993 standards. They will conduct In vitro evaluation using human cells to screen the glass compositions for cytotoxicity. Also, toxicity of polymeric scaffolds for glass will be examined.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2022–2023). Reported award amounts total $1,349,944. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Defense

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.